Type 2 diabetes mellitus (T2DM) is characterized by decreased plasma zinc levels and 15
Introduction 34
Type 2 diabetes mellitus (T2DM) is increasing worldwide due, in part, to rising rates of obesity 35 caused by poor diet [1] and physical inactivity. The global prevalence of diabetes among adults 36 over 18 years of age has increased from 4.7% in 1980 to 8.5% (422 million) in 2014 [2] . 37
While drugs for the management of T2DM are numerous, the lack of a thorough 38 understanding of the underlying causes of T2DM has prevented the development of a cure for 39 the condition. Numerous studies in the last several decades have observed decreased plasma zinc 40 levels [3] , loss of zinc [4] and effects of zinc supplementation on glycemic control [5] in T2DM, 41 but the underlying causes of the disturbances in zinc homeostasis or the role in T2DM remains 42 unclear. 43
The aim of this study was to identify the source of decreased zinc and zinc loss and to 44 discover a mechanism for the loss of zinc observed in T2DM. This study compared postprandial 45 plasma zinc levels between healthy controls and T2DM subjects to determine possible 46 differences in zinc-associated proteins. This study has identified the likely source of zinc loss as 47 bacterial zinc proteinases that cause the formation of activated A2M, which is then presumably 48 cleared through the LRP1 receptor pathway. Additionally, we also found that in the continued 49 presence of activated A2M, activation of the insulin receptor is impaired and results in a reduced 50 insulin response. 51 This study was approved by the New England Institutional Review Board (NEIRB, Needham, 56 MA US). This study recruited and gathered data from 9 volunteers, who included 6 diabetic or 57 prediabetic patients and 3 controls. The panel included one female and one Caucasian, and all 58 subjects were males of South Asian origin. The T2DM volunteer subjects had diabetic or 59 prediabetic ranges of fasting glucose levels above 110 mg/dL, and the control subjects were at 60 100 mg/dL or below. Subjects were informed of the research procedure and risks of blood draw, 61 and consent was obtained as per NEIRB guidelines. As no interventions were planned or 62 performed, this study was not classified as a clinical trial under the NIH definition. Blood draws 63 and tests were contracted and performed between June 2018 and June 2019 at a nationally 64 recognized certified commercial laboratory facility by professional personnel. Fasting blood 65 draw was performed after overnight fasting, and postprandial blood draw was performed 1 hour 66 after a light breakfast. 67
68

Zinc Test 69
Zinc level measurement in plasma was determined using a standard clinically approved test 70 number 945, offered by the national commercial laboratory. Blood was drawn at the testing 71 facility following the collection protocol for the zinc test. Both samples of unprocessed and 72 plasma depleted of albumin/Ig at the researchers' laboratory were returned to the clinical 73 laboratory for testing within the period recommended by guidelines for the zinc test. For zinc 74 level determination, 300 µl of plasma were typically albumin/Ig depleted and then reconstituted 75 with 300 µl of unprocessed plasma into a final volume of 900 µl using 1x phosphate-buffered 76 saline (PBS), resulting in a 3-fold dilution. This sample reconstitution was performed to bring 77 zinc levels above the detection threshold of 10 µg/dL for the liquid chromatography/Mass 78 Spectroscopy (LC/MS) protocol used for zinc level calculation at the commercial clinical 79 laboratory. In addition, two samples of 900 µl, one an unprocessed sample diluted 3x using 1x 80 PBS, and the other an unprocessed, undiluted plasma sample were tested for reference. The incubation (multiple treatments). There was a significant difference between single treatment 132 with A2MFF and multiple treatments with A2MFF in the presence of A2M. A single treatment 133 with A2MFF showed no significant difference when compared to treatment with A2M alone 134 (two-way ANOVA, P = 0.9548, P = 0.9549). There is a significant difference in insulin receptor 135 activation with multiple treatments with A2MFF when compared to treatment with A2M alone 136 (paired two-tailed t-test P = 0.0173, two-way ANOVA, P = 0.0027, P = 0.0148). 137
138
Results 139 140
Comparison of Postprandial Zinc Levels 141
We measured postprandial plasma zinc levels in subjects with T2DM and healthy controls before 142 and after albumin/Ig depletion. We found zinc levels in all subjects before albumin/Ig depletion 143 were in the normal range of 60-130 µg/dL. Zinc levels after albumin/Ig depletion were nearly 144 zero in the controls and significantly above zero in the T2DM subjects. This is shown as the 145 difference between zinc levels between unprocessed plasma and depleted plasma with a known 146 quantity of added plasma to bring values above the detection threshold (Fig 1) . In the controls 147 8 (samples 1-3), there was no significant difference between pre-and postdepletion plasma (paired 148 two-tailed t-test, P = 0.0572,). The T2DM group (samples 4-9), however, showed a significant 149 difference in pre-and postdepletion zinc levels (paired two tailed t-test, P = 0.0232). A 150 comparison of the controls vs. T2DM groups showed a significant difference between the groups 151 of 6.5 units (paired two-tailed t-test, P = 0.0280). A Gaussian distribution was assumed even 152 though the sample sizes were small. These findings suggest that there is a small fraction of 153 proteins with zinc affinity other than albumin/Ig in T2DM that are not present in healthy 154 controls. 155 156
Liquid Chromatography with Tandem Mass Spectrometry Based Protein Identification 157
To identify the zinc-associated proteins in the samples after albumin/Ig depletion, we analyzed 158 postprandial albumin/Ig-depleted plasma from each subject after filtration using Zn-IMAC and 159 liquid chromatography with tandem mass spectrometry (LC/MS/MS) for protein identification 160 and analysis. Of the 7 samples analyzed, 3 control subjects and 2 prediabetic patient showed zero 161 percent of bacterial proteinases, while 2 T2DM samples showed a minor amount of bacterial 162 proteinases. In the T2DM samples, the bacterial proteinases alone did not add up to the amount 163 of remaining zinc not associated with albumin/Ig. All samples showed that the majority protein 164 was alpha 2 macroglobulin (A2M) ( 
Measurement of Insulin Receptor Activation 174
The effect of non-activated A2M and activated, fast form A2M (A2MFF) on insulin activity was 175 measured. Commercially available purified A2M and A2MFF were subjected to one of two 176 treatments at varying insulin concentrations. Treatment consistent of a single dose of activated 177 A2M (A2MFF single) or multiple additions of activated A2M (A2MFF multiple) every 30 178 minutes for the duration of the 3-hour incubation in the presence of 1.2 µg/ml of non-activated 179 A2M, at a concentration of 0.24 µg/µl, which approximately a fifth of the included A2M 180 concentration. Insulin receptor activation was assessed by measuring relative luminescence units 181 using the β -galactosidase assay of the PathHunter ® insulin receptor activation assay. The results 182 showed a large, significant decrease in insulin receptor activation following A2MFF treatment 183 every 30 minutes relative to a single treatment of A2MFF (paired two-tailed t-test, P = 0.0173). 184
There was no significant difference between the effect of A2M alone and A2M with a single 185 A2MFF treatment on insulin receptor activation (paired two-tailed t-test, P = 0.0615) (Fig 2) . We 186 10 performed a two-way ANOVA analysis and observed a significant difference in insulin receptor 187 activation at two different concentrations (300 ng/mL, 100 ng/mL) between A2M with a single 188 treatment of A2MFF (two-way ANOVA, P = 0.9548, P = 0.9549), which showed no significant 189 difference compared with A2M alone, and A2M with multiple treatments of A2MFF (two-way 190 ANOVA, P = 0.0027, P = 0.0148), which showed in a significant difference compared to A2M 191 alone (Fig 2) . These results demonstrate that insulin receptor activation is significantly reduced 192 in the presence of A2MFF, likely due to interference with the ability of insulin to access the 193 insulin receptor. 194
We also performed insulin receptor activation assays individually with A2M, A2MFF. 195
We found there was no significant difference in insulin receptor activation between A2M and a 196 single treatment with A2MFF (paired two-tailed t-test, P = 0.2514). Furthermore, in a separate 197 experiment, we used almost twice the concentration of A2MFF (0.44 µg/µl) compared to that in 198 a previous experiment, with an increased volume (15% of the reaction volume compared to 3% 199 of the reaction volume in the previous experiment), in the presence of A2M. We found a similar 200 reduction in insulin receptor activation following both single (paired two-tailed t-test , P = 201 0.0043) and multiple treatments with A2MFF (paired two-tailed t-test, P = 0.0016) when 202 compared with A2M alone. The reduction in insulin receptor activation in the large single 203 treatment group was prolonged and in the same range as that of the group with multiple 204 treatments of A2MFF (data not shown). 205 206
Discussion 207
A prominent characteristic of T2DM is decreased plasma zinc levels and hyperzincuria, for 208 which a cause is unknown [7] . We hypothesized that zinc loss is due to the association of zinc 209 11 with a different set of proteins that may be in a biologically unavailable form. To explore this 210 possibility and considering that a majority of zinc in plasma is associated with albumin/Ig [7,8], 211 we compared postprandial albumin/Ig-depleted plasma zinc levels between healthy controls and 212 T2DM subjects. Our results showed some amount of remaining zinc in albumin/Ig depleted 213 plasma in T2DM subjects but not in healthy controls (Fig 1) . This finding indicated that a small 214 but significant portion of zinc is bound to proteins other than albumin/Ig in T2DM. 215
To identify the proteins associated with the remaining zinc in albumin/Ig depleted 216 postprandial plasma of T2DM subjects, we purified the depleted plasma on a zinc immobilized 217 metal affinity chromatography (Zn-IMAC) column and analyzed the proteins using LC/MS/MS. 218
The results showed that the majority of protein was A2M in both the T2DM subjects and 219 controls. This finding is consistent with similar observations in a previous study [8] . Some 220 bacterial proteinases were observed in 2 T2DM subjects but none in healthy controls or 1 221 prediabetic subject (Table 1 ). The total amount of bacterial zinc proteinases did not add up to the 222 level of remaining zinc. Prediabetic sample were not different from the control samples for 223 bacterial zinc proteinases, even though we detected some remnant zinc after albumin/Ig 224 depletion. A previous study showed increased A2M levels with a reduced trypsin binding 225 capacity in diabetes [6] . We inferred that these results, albeit indirectly, indicated that the 226 remaining zinc after albumin/Ig depletion likely came from activated A2M proteins that have 227 trapped bacterial zinc proteinases, since A2M is a pan-protease inhibitor that traps free 228 proteinases, resulting in A2MFF. In the prediabetic case, free bacterial proteinases may not be 229 detected because they may be obscured when captured by A2M, without exceeding the capture 230 threshold for levels of activated A2M [9] . 231
Studies have shown that proteinase-activated A2M (A2MFF) binds numerous receptors, 232 including, LRP1, growth factors and cytokines [10] . We hypothesized that A2MFF may also 233 bind the insulin receptor. We tested this possibility with an insulin receptor activation assay. We 234 measured insulin receptor activation following treatment with non-activated A2M with either 235 single or multiple treatments with activated A2M (A2MFF). Since activated A2M is rapidly 236 cleared away by the LRP1 receptor in approximately 2-4 minutes [11, 12] , multiple treatments 237 with activated A2M were used to replace activated A2M that would be cleared away during the 238 long incubation, thereby providing a continuous presence of activated A2M and revealing its 239
effects. 240
We observed a significant decrease in insulin receptor activation after multiple treatments 241 with A2MFF (0.24 µg/µl) compared to a single treatment with A2MFF (0.24 µg/µl) (Fig 2) . We 242 also observed a decrease in insulin receptor activation with a single high dose (0.44 µg/µl) of 243 A2MFF (data not shown), similar to the results following multiple treatments with A2MFF at a 244 lower concentration. This result demonstrates that the presence of A2MFF is causing an 245 impairment of insulin receptor activation tested in a dose response to insulin. While A2MFF may 246 interact with insulin itself, since A2MFF has been shown to bind cell surface receptors like the 247 NGS receptor [13], we suggest that A2MFF likely binds the insulin receptor. This action would 248 help protect the insulin receptor from the detrimental actions of free bacterial proteinases. Loss 249 of their insulin receptors would be catastrophic for cells; therefore, this critical " receptor-250 protective" action by A2MFF would be effective as long as bacterial proteinase-activated A2M 251 and therefore likely destructive free proteinases were present. Then, the "receptor-protective" 252 effect would shield the insulin receptor and presumably prevent the activation of the insulin 253 receptor by insulin. Therefore, insulin signaling and response would be diminished as in the 254 13 phenomenon of insulin resistance. Our hypothesis is supported by a study showing that 255 functional inactivation of IGF-1 and insulin receptors in skeletal muscle causes T2DM [14] . 256
Additionally, myriad effects, such as excessive secretion of glucagon in pancreatic α cells [15] or 257 reduced insulin-mediated potentiation of glucose-stimulated insulin secretion in insulin resistant 258 humans affected by the role of insulin receptor in glucose homeostasis 16,20] and decreases in 259 beta cell mass [17] , can be explained by a "receptor-protective" effect of A2MFF on the insulin 260 receptor to shield it from the destructive effect of free bacterial proteinases. We also suggest that 261 the clearance of the bacterial zinc proteinase-activated A2M through the LRP1 receptor is the 262 cause of the observed effect of hyperzincuria and zinc loss in T2DM. Further, the increased LDL 263 levels observed in T2DM could be due to occupation of the LRP1 via clearance of activated 264 A2M, causing a slowdown in turnover of LDL. Furthermore, duodenal mucosal removal 265 abrogates hyperglycemia [18, 19] , which provides evidence that bacterial zinc proteinases play a 266 central role in T2DM. 267
There is currently no explanation for a unified hypothesis that links the defects found in 268 T2DM pathogenesis, including insulin resistance and beta cell dysfunction [20] . By providing 269 evidence for the underlying cause, linking well-known and not fully elucidated phenomena in 270 T2DM-zinc loss and insulin resistance-and describing the correlations to related effects, we 271 offer a unifying explanation and demonstrate a possible mechanism of this disease. 272
In conclusion we believe that the mucosal barrier in the duodenum is compromised due to 273 goblet cell dysfunction or damage caused by antibiotics [21] [22] [23] . This phenomenon allows 274 proteinases produced by discrepant gut bacteria to cross the mucosal layer [23] and be absorbed 275 into the bloodstream. Once in the circulation, these bacterial zinc proteinases are bound by A2M, 276 resulting in activated A2M (A2MFF) [6], whose "receptor-protective" action, as we have 277 14 described, above causes a diminished insulin response that is perceived as insulin resistance and 278 leads to T2DM. 279 280 Acknowledgments 281
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